NAD+ Precursors vs SS-31
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: NMN, NR
While not peptides, NAD+ precursors are frequently discussed alongside peptides in longevity circles. They boost cellular NAD+ levels, supporting energy metabolism and sirtuin activity.
Also: Elamipretide, Bendavia
A mitochondria-targeted peptide that improves cellular energy production. FDA approved for Barth syndrome (September 2025) as FORZINITY, the first approved mitochondria-targeted therapeutic.
Key Comparison Insights
- SS-31 is FDA approved, while NAD+ Precursors remains in research stages.
- Both peptides belong to the Anti-Aging category, suggesting similar primary applications.
- SS-31 has stronger research evidence (FDA Approved) compared to NAD+ Precursors (Human Trials).
Detailed Comparison
| Attribute | NAD+ Precursors | SS-31 |
|---|---|---|
| Category | Anti-Aging | Anti-Aging |
| FDA Status | Not FDA Approved | FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | NMN and NR are converted to NAD+ in cells. NAD+ is essential for mitochondrial function, DNA repair, and sirtuin enzyme activity. Sirtuins regulate metabolism, stress response, and longevity pathways. NAD+ levels decline with age. | SS-31 concentrates 1000-fold in mitochondria, binding to cardiolipin on the inner membrane. It optimizes electron transport chain function, reduces reactive oxygen species, and prevents cardiolipin peroxidation during cellular stress. |
| Common Dosing | Limited community data available See research protocols | 40 mg subcutaneous daily Once daily |
| Administration | Oral (capsules, sublingual) | Subcutaneous injection or IV infusion |
| Typical Duration | Ongoing supplementation | Variable by condition |
| Best Time to Take | Morning or before bed | Morning |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Animal studies show improved metabolic function, enhanced exercise capacity, and extended healthspan. Human trials demonstrate safety and NAD+ elevation. Long-term benefits in humans still being established. David Sinclair's research popularized the field. | FDA approved for Barth syndrome in September 2025 under accelerated approval. Ongoing trials for dry age-related macular degeneration and primary mitochondrial myopathy. Studies show improved cardiac function, exercise capacity, and mitochondrial efficiency. |
Frequently Asked Questions: NAD+ Precursors vs SS-31
What is the difference between NAD+ Precursors and SS-31?
NAD+ Precursors is a anti-aging peptide that while not peptides, nad+ precursors are frequently discussed alongside peptides in longevity circles. they boost cellular nad+ levels, supporting energy metabolism and sirtuin activity. SS-31 is a anti-aging peptide that a mitochondria-targeted peptide that improves cellular energy production. fda approved for barth syndrome (september 2025) as forzinity, the first approved mitochondria-targeted therapeutic. The main differences lie in their mechanisms of action and clinical applications.
Which is better, NAD+ Precursors or SS-31?
Neither is universally "better" - the choice depends on your specific goals. NAD+ Precursors is typically used for anti-aging purposes, while SS-31 is used for anti-aging. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can NAD+ Precursors and SS-31 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using NAD+ Precursors and SS-31 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.